current
ebola
viru
ebov
detect
method
costli
impract
epidem
scenario
differ
immunebas
assay
report
detect
quantif
ebola
viru
ebov
protein
particular
sever
monoclon
antibodi
mab
describ
bind
capsid
glycoprotein
gp
ebov
gp
howev
current
avail
platform
design
product
fulllength
mab
cumbersom
costli
use
antibodi
fragment
rather
fulllength
antibodi
might
repres
costeffect
altern
develop
diagnost
possibl
even
therapeut
altern
ebov
report
design
express
three
recombin
antigp
mab
fragment
escherichia
coli
cultur
fragment
contain
heavi
light
variabl
portion
three
wellstudi
antigp
fulllength
mab
consequ
name
respect
three
fragment
exhibit
specif
antigp
bind
activ
elisa
experi
compar
fulllength
antigp
antibodi
ie
order
magnitud
easili
econom
produc
bacteri
cultur
antibodi
fragment
might
repres
use
effect
low
cost
altern
fulllength
antibodi
ebola
relat
captur
diagnost
applic
recent
ebola
outbreak
began
west
africa
decemb
reveal
poorli
prepar
medic
world
effect
face
diseas
march
case
document
west
africa
impli
great
econom
logist
burden
current
method
diagnos
presenc
ebola
viru
ebov
biolog
sampl
reli
mainli
pcr
method
abl
detect
ebov
low
viral
load
high
accuraci
reproduc
requir
special
instrument
train
personnel
impos
heavi
restrict
use
pcr
ebola
epidem
scenario
ebola
diagnost
altern
includ
use
immunolog
method
base
polyclon
monoclon
antibodi
mab
howev
product
fulllength
antibodi
complex
process
engin
perspect
current
avail
product
platform
suffici
effect
provid
requir
rapid
respons
emerg
antibodi
fragment
present
sever
potenti
advantag
use
fulllength
mab
express
easili
produc
readili
econom
bacteri
cultur
ie
escherichia
coli
cultur
larg
quantiti
produc
g
mab
fragment
bacteri
system
would
cost
cost
produc
g
full
length
mab
cho
cell
system
prefer
product
platform
mab
furthermor
novel
express
purif
technolog
greatli
simplifi
purif
recombin
protein
produc
e
coli
purif
tradit
consid
seriou
drawback
widelyus
express
system
antibodi
fragment
contain
variabl
region
fulllength
antibodi
conceptu
retain
bind
specif
fulllength
antibodi
gener
decreas
bind
affin
antibodi
fragment
compar
bind
intact
antibodi
document
howev
fragment
molecul
tailor
genet
engin
improv
affin
stabil
mani
design
adjust
possibl
antibodi
fragment
respect
size
pharmacokinet
immunogen
specif
even
effector
function
use
antibodi
fragment
diagnos
presenc
viral
particl
recommend
report
context
number
viral
diseas
properli
optim
mab
fragment
effect
full
length
mab
term
molecular
affin
exvivo
diagnost
applic
sinc
fragment
molecul
much
smaller
correspond
mab
approxim
one
sixth
mab
mass
argu
use
optim
mab
impli
higher
bind
efficaci
per
unit
mass
paper
aim
produc
three
antibodi
fragment
contain
variabl
region
mab
wellstudi
antiebov
fulllength
mab
briefli
mab
one
three
fulllength
mab
contain
mapp
biopharmaceut
formul
proven
protect
lethal
ebov
challeng
nonhuman
primat
fulllength
mab
also
constitu
zmapp
mab
cocktail
recent
administ
human
patient
appar
good
result
mab
bind
glycan
cap
region
glycoprotein
gp
mab
one
constitu
zmab
anoth
antiebov
fulllength
mab
cocktail
mapp
biopharmaceut
bind
mucinlik
domain
mld
gp
highli
glycosyl
region
cleav
upon
intern
viral
particl
host
cell
fulllength
mab
origin
isol
ebola
diseas
ebd
survivor
structur
mab
bound
trimer
gp
character
detail
lee
et
al
lee
saphir
three
antibodi
fragment
design
produc
respect
name
fulllength
counterpart
mab
mab
mab
three
fragment
express
escherichia
coli
produc
use
straightforward
fedbatch
cultur
protocol
instrument
reactor
demonstr
use
antibodi
fragment
captur
gp
elisa
experi
three
anti
gp
ebov
antibodi
fragment
inspir
fulllength
mab
design
silico
express
e
coli
cultur
fig
briefli
design
dna
construct
mab
fragment
contain
light
variabl
region
lv
heavi
variabl
region
hv
correspond
mab
lv
hv
region
connect
glycineserin
linker
construct
fig
includ
region
encod
nterminu
facilit
purif
use
ni
imac
column
fig
case
small
portion
light
constant
region
heavi
constant
region
mab
includ
correspond
construct
tabl
construct
optim
e
coli
express
synthet
colleagu
dna
san
francisco
ca
built
plasmid
clone
plyss
strain
plyss
strain
product
purif
mab
fragment
e
coli
cultur
luriabertani
medium
ampicillin
lbamp
supplement
gl
glucos
gl
potassium
phosphat
dibas
gl
magnesium
sulfat
mll
trace
nutrient
zinc
chlorid
gl
cobalt
chlorid
gl
sodium
molybd
gl
calcium
chlorid
gl
boric
acid
gl
hydrochlor
acid
mll
fulli
instrument
bioreactor
applikon
netherland
cultur
condit
ph
rpm
growth
phase
rpm
induct
protein
product
induc
use
isopropyl
thiogalactosid
iptg
approxim
hour
initi
process
presenc
protein
confirm
sdspage
antihistag
western
blot
fig
cell
recov
centrifug
z
hk
herml
labortechnik
germani
fix
angl
rotor
centrifug
x
g
min
resuspend
pb
buffer
mm
pb
mm
nacl
ph
ratio
ml
buffer
per
g
biomass
wet
weight
cell
disrupt
emulsiflex
avestin
canada
highpressur
homogen
protocol
three
cycl
follow
first
cycl
set
psi
follow
two
cycl
perform
psi
cell
lysat
centrifug
z
hk
herml
labortechnik
germani
centrifug
x
g
min
pellet
resuspend
inclus
bodi
ib
wash
buffer
mm
pb
mm
nacl
mm
ethylenediaminetetraacet
acid
urea
vv
triton
ph
ratio
ml
buffer
per
g
pellet
wet
weight
suspens
wash
vigor
minut
room
temperatur
final
wash
pb
buffer
implement
result
pellet
resuspend
solubil
buffer
mm
pb
mm
nacl
urea
mm
dithiothreitol
mm
imidazol
ph
stir
vigor
room
temperatur
overnight
centrifug
x
g
minut
supernat
contain
solubil
ib
microfilt
membran
pall
corpor
ny
store
purifi
mab
fragment
solut
obtain
immobil
metalaffin
chromatographi
imac
ml
trap
ff
ge
healthcar
uk
column
precharg
ni
explor
ge
healthcar
uk
chromatographi
system
oncolumn
protein
refold
achiev
elimin
chaotrop
agent
use
cv
linear
fulllength
mab
wide
studi
previou
literatur
mab
target
epitop
differ
region
gp
protein
ebola
viru
ebov
nativ
form
gp
trimer
compos
three
monom
monom
compos
subunit
yellow
oval
subunit
orang
stalk
bind
linear
epitop
region
locat
mucinlik
domain
mld
region
gp
light
yellow
small
oval
specif
bind
region
known
locat
within
region
yellow
oval
bind
region
well
character
compris
residu
yellow
oval
orang
stalk
b
antibodi
fragment
contain
variabl
region
respons
specif
gp
recognit
fulllength
mab
design
base
upon
c
schemat
represent
dna
construct
use
express
sequenc
linker
peptid
shown
red
first
seri
assay
commerci
avail
recombin
version
gp
attach
surfac
elisa
micropl
differ
fulllength
mab
antibodi
fragment
test
specif
bind
fig
experi
solut
histag
recombin
gp
rgp
express
insect
cell
integr
biotherapeut
bioservic
gaithersburg
md
usa
dispens
well
incub
h
wash
twice
pbstween
solut
afterward
commerci
block
solut
pierc
rockford
il
usa
dispens
per
well
incub
ambient
temperatur
minut
wash
twice
pbstween
solut
gp
bind
affin
two
differ
fulllength
monoclon
antibodi
name
mab
integr
biotherapeut
bioservic
gaithersburg
md
usa
infliximab
commerci
antirheumatoid
arthriti
therapeut
mab
janssen
biotech
horsham
pa
usa
three
antibodi
fragment
evalu
purpos
solut
mab
mab
fragment
dispens
differ
well
incub
h
room
temperatur
wash
three
time
pbstween
solut
variat
elisa
format
fig
either
solut
antihistidin
tag
igg
abd
serotec
kidlington
uk
dispens
well
incub
h
room
temperatur
wash
twice
pbstween
solut
commerci
block
solut
dispens
per
well
incub
ambient
temperatur
minut
wash
twice
pbstween
solut
afterward
solut
histag
rgp
express
insect
cell
dispens
well
solut
histag
harbd
express
inhous
incub
h
wash
twice
pbstween
solut
gp
ha
bind
affin
two
differ
fulllength
monoclon
antibodi
mab
antibodi
fragment
evalu
briefli
solut
mab
mab
fragment
dispens
differ
well
incub
h
room
temperatur
wash
three
time
pbstween
solut
elisa
format
gp
experi
bind
gp
fragment
reveal
use
solut
polyclon
antihistidin
igg
mark
hors
radish
peroxidas
gray
neg
control
consist
surfac
gp
harbd
expos
antigp
fragment
c
plot
absorb
signal
measur
elisa
experi
correspond
assay
well
either
gp
orang
bar
harbd
red
bar
expos
burgundi
fragment
green
fragment
blue
fragment
absorb
signal
normal
absorb
valu
neg
control
black
bar
symbol
mab
fragment
present
fig
error
bar
indic
standard
deviat
four
repeat
independ
elisa
experi
horizont
black
line
indic
signific
differ
group
p
p
p
specif
bind
gp
evalu
elisa
experi
rgp
yellow
oval
orang
stalk
attach
assay
surfac
treat
antihistidin
igg
grey
ys
experi
bind
gp
fragment
reveal
use
solut
polyclon
antihistidin
igg
mark
hors
radish
peroxidas
grey
ys
mark
fluoresc
star
b
neg
control
consist
surfac
gp
hargb
expos
antigp
fragment
c
plot
absorb
signal
measur
elisa
experi
correspond
assay
well
either
gp
orang
bar
expos
burgundi
fragment
green
fragment
blue
fragment
absorb
signal
normal
absorb
valu
neg
control
black
bar
symbol
mab
fragment
present
fig
error
bar
indic
standard
deviat
four
repeat
independ
elisa
experi
horizont
black
line
indic
signific
differ
group
p
p
express
set
three
antigp
ebov
monoclon
antibodi
fragment
e
coli
cultur
fragment
contain
variabl
region
heavi
light
three
wellstudi
fulllength
mab
refer
literatur
fig
correspond
mab
fragment
refer
protein
singlechain
variabl
fragment
scfv
smallest
stabl
antibodi
fragment
capabl
specif
bind
antigen
gener
recombin
polypeptid
compos
antibodi
variabl
lightchain
amino
acid
sequenc
vl
link
variabl
heavychain
sequenc
vh
design
peptid
amino
acid
link
carboxyl
terminu
vl
sequenc
amino
terminu
vh
sequenc
strictli
design
scfv
sinc
also
contain
portion
constant
heavi
constant
light
chain
fulllength
mab
see
fig
tabl
fig
show
sdspage
protein
profil
sampl
bacteri
suspens
produc
strain
cultur
instrument
l
bioreactor
observ
similar
protein
profil
similar
degre
express
three
fragment
measur
sdspage
gel
western
blot
fig
cell
induc
iptg
h
cultur
induct
band
protein
kda
kda
respect
observ
agreement
molecular
weight
fragment
fig
addit
band
lane
suggest
occurr
certain
degre
fragment
cultur
experiment
condit
report
practic
protein
interest
accumul
inclus
bodi
maximum
biomass
concentr
nonoptim
batch
cultur
gl
product
concentr
h
cultur
estim
mgl
cultiv
mab
fragment
recov
purifi
use
protocol
describ
materi
method
overal
yield
mgl
mg
antibodi
fragment
per
l
cultur
media
reactor
obtain
nonoptim
process
final
product
puriti
higher
fig
bind
capac
antibodi
fragment
commerci
recombin
ebov
gp
rgp
express
insect
cell
determin
elisa
experi
fig
first
round
experi
rgp
commerci
attach
assay
well
plate
surfac
either
full
length
mab
posit
control
dispens
concentr
assay
harbd
influenza
attach
well
surfac
use
neg
control
experi
mab
confirm
attach
surfac
function
rgp
reveal
addit
bind
commerci
rabbit
polyclon
antiigg
case
experi
use
fragment
polyclon
anticonst
region
igg
case
experi
use
mab
three
antibodi
fragment
exhibit
select
gp
bind
activ
elisa
experi
signific
differ
bind
activ
select
found
among
fig
show
comparison
bind
activ
gp
orang
column
determin
elisa
assay
gp
attach
assay
surfac
mab
exhibit
highest
gpbind
activ
follow
absorb
signal
ratio
posit
bind
sampl
blank
fragment
ad
respect
run
addit
neg
control
use
human
serumfrom
mexican
patient
expos
influenza
presum
neg
ebolainstead
pb
neg
control
exhibit
similar
absolut
absorb
signal
pb
sampl
although
fragment
bind
gp
affin
select
lowest
among
three
fragment
test
probabl
explan
could
natur
epitop
conform
epitop
includ
domain
residu
analog
fragment
interact
residu
proper
bind
misalign
variabl
region
fragment
could
conceiv
caus
decreas
bind
efficaci
addit
epitop
less
expos
sinc
access
epitop
steric
impair
shown
proper
align
gp
molecul
could
favor
access
antibodi
fragment
test
hypothesi
conduct
bind
experi
use
slightli
modifi
elisa
format
layer
antihistidin
igg
dispens
surfac
assay
well
later
addit
histag
rgp
direct
attach
rgp
assay
surfac
favor
particular
align
molecul
layer
antihistidin
antibodi
induc
prefer
orient
histag
gp
fig
harbd
molecul
inde
improv
perform
elisa
experi
achiev
use
antihistidin
igg
layer
fig
averag
gp
bind
affin
normal
neg
control
increas
fig
fig
interestingli
averag
gpbind
affin
two
fragment
decreas
averag
appar
gp
bind
affin
decreas
normal
unit
appar
gp
bind
affin
decreas
normal
unit
see
fig
taken
togeth
result
suggest
effect
molecular
orient
align
relev
design
strategi
diagnosi
captur
blockag
ebov
also
suggest
may
use
includ
one
antibodi
fragment
actual
cocktail
maxim
bind
system
steric
effect
appear
import
molecular
level
implic
design
protocol
treatsensit
surfac
elisa
method
fig
show
result
gp
elisa
experi
evalu
two
differ
antihistidin
igg
surfac
densiti
associ
use
two
differ
antihistidin
igg
coat
solut
concentr
nonspecif
bind
harbd
also
measur
fig
sensit
assay
higher
surfac
lower
antihistidin
igg
densiti
averag
ratio
absorb
signal
posit
sampl
gp
neg
control
unit
respect
assay
surfac
treat
antihistidin
igg
fig
ratio
increas
unit
assay
conduct
surfac
treat
gp
evalu
elisa
experi
layer
antihistidin
igg
first
dispens
surfac
assay
well
grey
ys
later
attach
rgp
layer
yellow
oval
orang
stalk
presenc
mab
fragmentgp
complex
reveal
addit
solut
antihistidin
polyclonaligg
grey
ys
green
fluoresc
star
c
neg
control
experi
consist
use
infliximab
antirheumatoid
arthriti
therapeut
mab
black
mab
pink
variabl
region
instead
antigp
mab
fragment
bind
activ
term
arbitrari
absorb
unit
determin
elisa
experi
fulllength
black
mab
green
variabl
region
burgundi
fragment
green
fragment
blue
fragment
gp
yellow
oval
orang
stalk
absorb
read
neg
control
also
shown
pink
bar
panel
show
result
experi
conduct
two
differ
concentr
antihistidin
igg
solut
use
treat
assay
surfac
error
bar
indic
standard
deviat
least
two
repeat
independ
elisa
experi
normal
perform
horizont
black
line
indic
signific
differ
group
p
p
p
antihistidin
igg
fig
select
measur
ratio
absorb
signal
gp
harbd
bind
assay
increas
significantli
experi
use
assay
surfac
treat
antihistidin
igg
gpha
respect
compar
experi
conduct
gp
directli
attach
assay
surfac
gpha
experi
also
includ
fulllength
mab
infliximab
commerci
antirheumatoid
arthriti
therapeut
mab
posit
neg
control
respect
fig
averag
ratio
absorb
signal
due
gp
gp
bind
experi
use
antihistidin
igg
coat
solut
respect
fig
result
provid
refer
indic
level
sensit
expect
use
antigp
ebov
fragment
instead
commerci
avail
fulllength
mab
consid
use
direct
comparison
bind
affin
fulllength
mab
antibodi
fragment
note
mab
target
differ
epitop
gp
also
reveal
gp
complex
use
mark
polyclon
igg
cocktail
instead
antihistidin
igg
data
shown
also
present
elisa
result
deriv
use
fig
three
fragment
produc
test
exhibit
signific
differ
bind
affin
gp
order
magnitud
ebov
gp
bind
absolut
guarante
three
mab
fragment
effect
detect
ebov
particl
patient
sampl
research
use
sampl
contain
actual
ebov
particl
sampl
ebola
diseas
patient
must
conduct
fulli
valid
diagnost
use
peptid
show
three
antibodi
fragment
design
correspond
fulllength
mab
variabl
region
taken
abl
bind
commerci
avail
gp
compar
affin
lower
order
magnitud
seen
previous
studi
commerci
avail
full
length
antigp
mab
find
substanti
relev
design
gp
detect
method
even
therapeut
strategi
use
antibodi
fragment
rather
full
length
antibodi
significantli
reduc
cost
product
ebola
diagnost
devic
product
mab
fragment
bacteri
cultur
costeffect
proposit
product
fulllength
mab
insect
mammalian
cell
cultur
evalu
bind
affin
gp
one
three
fragment
elisa
experi
commerci
histag
rgp
either
directli
attach
assay
surfac
attach
via
layer
antihistidin
igg
three
fragment
bound
gp
result
suggest
appar
sensit
assay
depend
orientationalign
rgp
molecul
assay
surfac
also
found
concentr
antihistidin
solut
use
prepar
surfac
rgp
bind
relev
sensibl
select
assay
antibodi
fragment
use
addit
toolbox
diagnosi
presenc
gp
biolog
sampl
may
allow
design
less
expens
highloadhigh
resolut
ebov
detect
system
instanc
nanoparticl
highli
load
antibodi
fragment
could
repres
costeffect
altern
detect
captureconcentr
gp
ebov
particl
gener
sens
deriv
function
mab
fragment
wellstudi
full
length
mab
produc
fragment
bacteri
cultur
might
costeffect
expediti
strategi
react
diagnost
need
epidem
even
pandem
event
offer
first
proofofprincipl
particular
case
ebola
